Preliminary Report of RTOG 9508: A Phase III Trial Comparing Whole Brain Irradiation Alone Versus Whole Brain Irradiation Plus Stereotactic Radiosurgery for Patients with Two or Three Unresected Brain Metastases

Joel W. Goldwein, MD
OncoLink co-Editor-In-Chief
Ultima Vez Modificado: 23 de octubre del 2000

Share article


Presenter: P. W. Sperduto
Affiliation: Radiation Therapy Oncology Group


Summary:

Brain metastases develop in approximately 25% of all cancer patients. Management with stereotactic radiotherapy for patients with 3 or less solitary lesions remains an area of controversy. This preliminary analysis is of a group of patients treated with whole brain radiation versus whole brain radiotherapy plus a radiosurgical boost.


Methods:

  • Patients with 2 or 3 solitary metastases were evaluated in this analysis

  • Patients were randomized to either 3750 cGy/15 fractions whole brain RT or 3750 cGy/15 fractions whole brain RT + 1500 cGy to 2400 cGy radiosurgical boost (size dependent)


Results:

  • The groups were well balanced for parameters such as KPS, numbers of lesions, and other factors

  • Median survival in the 2 arms were 5.8 and 6.7 months, and were not significantly different.

  • Local control was marginally better in the stereotactic boost arm vs. the whole brain alone arm

  • There was a 20% improvement in Karnofsky status in the radiosurgery arm versus 0% in the whole brain alone arm, and a similar reduction in steroid dependence among patients receiving boost RT.

  • There was no grade 4 or 5 toxicity in either arm, and 4% grade III toxicity in the boost arm versus 0% in the no-boost arm


Author's Conclusions:

  • In patients with 2 or 3 brain metastases, stereotactic boost following whole brain RT has no impact on survival, improves local control, and may improve quality of life


Clinical/Scientific Implications:

  • Patients with 2 or 3 brain metastases may benefit from such therapy in terms of local control and quality of life

  • Further study will be required to identify subsets of patients who derive the most benefit from this therapy.


News
ASTRO: Avoiding Hippocampus Preserves Memory in Brain Mets

Oct 4, 2013 - For patients with brain metastases, hippocampal avoidance whole brain radiotherapy is associated with less memory decline at four months, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 22 to 25 in Atlanta.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información